




| | | | | | |
|---|--------------------------------------|--------------------------------------|--|---|---------------------------------|
| AMENDMENT TRANSMITTAL LETTER (Small Entity) | | | | Docket No. 13257-00040 (UMD-0096) | |
| Applicant(s): Ron et al. | | | | | |
| Application No. 09/830,176 | Filing Date April 23, 2001 | Examiner Joseph T. Weitach | Customer No. 46046 | Group Art Unit 1632 | Confirmation No. 2969 |
| Invention: MYELOID PRECURSOR CELL USEFUL FOR GENE THERAPY AND FOR MODULATION OF IMMUNE RESPONSES | | | | | |
|  COMMISSIONER FOR PATENTS: | | | | | |
| Transmitted herewith is an amendment in the above-identified application. | | | | | |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 | | | | | |
| The fee has been calculated and is transmitted as shown below. | | | | | |
| CLAIMS AS AMENDED | | | | | |
| | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST # PREV. PAID FOR | NUMBER EXTRA CLAIMS PRESENT | RATE | ADDITIONAL FEE |
| TOTAL CLAIMS | 5 - | 20 = | 0 | x \$25.00 | \$0.00 |
| INDEP. CLAIMS | 2 - | 6 = | 0 | x \$100.00 | \$0.00 |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> | | | | | \$0.00 |
| TOTAL ADDITIONAL FEE FOR THIS AMENDMENT | | | | | \$0.00 |
| <input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | |
|  _____ Signature | | | Dated: September 6, 2005 | | |
| Jane Massey Licata Reg. No. 32,257 <div style="text-align: center;">Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053</div> | | | I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ (Date) _____ Signature of Person Mailing Correspondence _____ Typed or Printed Name of Person Mailing Correspondence | | |
| cc: | | | | | |

09-07-05

AF
JAW



RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 13257-00040 (UMD-0096)
Inventors: Ron et al.
Serial No.: 09/830,176
Filing Date: April 23, 2001
Examiner: Woitach, Joseph T.
Customer No.: 46046
Group Art Unit: 1632
Confirmation No.: 2969
Title: A Myeloid Precursor Cell Useful for Gene
Therapy and for Modulation of Immune
Responses

"Express Mail" Label No. EV794824816US
Date of Deposit September 6, 2005

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Commissioner for Patents, Mail Stop AF,
P. O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents
Mail Stop AF
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Reply Under 37 C.F.R. § 1.116

This is a reply to the Office action mailed June 3, 2005 setting a three (3) month statutory period for reply. Please enter the following remarks and amendments into the record.

Amendments to the Claims are reflected in the listing of claims which begin on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.